MIRM · Mirum Pharmaceuticals, Inc.
AI read · Good for MIRM
The AI's read
That change shows Cantor sees more value in Mirum's shares. Its rating also stayed positive. Still, this is an analyst's opinion, not a new result from Mirum.
Cantor Fitzgerald kept its positive rating on Mirum Pharmaceuticals and increased its price target from $155 to $160.
Good for MIRM
Cantor raised its target price for Mirum and kept its positive rating. This favors Mirum's shares, but the report gives an analyst's view, not a new company result.
Get alerts for MIRM
Follow Mirum Pharmaceuticals, Inc. (MIRM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MIRMFree on the App Store and Google Play, or on the web.